Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

4.0K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

519
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
519
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

855
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
855

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curcumin and Berberine Arrest Maturation and Activation of Dendritic Cells Derived from Lupus Erythematosus Patients.

Current molecular pharmacology·2024
Same author

Antitumor effects of curcumin: A lipid perspective.

Journal of cellular physiology·2019
Same author

MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy.

Trends in pharmacological sciences·2018
Same author

Raloxifene attenuates oxidative stress and preserves mitochondrial function in astrocytic cells upon glucose deprivation.

Journal of cellular physiology·2018
Same author

Metallo-beta-Lactamase-producing Pseudomonas aeruginosa in Iran: a systematic review and meta-analysis.

Le infezioni in medicina·2018
Same author

Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment.

Journal of cellular physiology·2018

Related Experiment Video

Updated: Mar 8, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

PCSK9 and diabetes: is there a link?

Amir Abbas Momtazi1, Maciej Banach2, Matteo Pirro3

  • 1Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran.

Drug Discovery Today
|January 24, 2017
PubMed
Summary

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors effectively lower cholesterol but their impact on diabetes mellitus (DM) remains unclear. This review examines PCSK9

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Experiment Videos

Last Updated: Mar 8, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Metabolic Diseases

Background:

  • Diabetes mellitus (DM) significantly elevates cardiovascular disease (CVD) risk.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent lipid-lowering agents.
  • Existing research suggests a link between PCSK9 levels, glycemic control, and type 2 DM (T2DM) risk, though genetic data is conflicting.

Purpose of the Study:

  • To evaluate the association between PCSK9 status and DM incidence and control.
  • To review preclinical and clinical evidence regarding PCSK9 and diabetes.
  • To identify molecular mechanisms influencing PCSK9 expression in diabetic conditions.

Main Methods:

  • Systematic review of epidemiological, preclinical, and clinical studies.
  • Analysis of genetic findings related to PCSK9 and DM.
  • Investigation of molecular pathways regulating PCSK9 in diabetes.

Main Results:

  • Evidence suggests a complex relationship between PCSK9 and DM.
  • The precise impact of PCSK9 inhibitors on glycemic control in diabetic patients requires further clarification.
  • Molecular mechanisms underlying PCSK9 regulation in DM are being elucidated.

Conclusions:

  • The role of PCSK9 in diabetes pathogenesis and management is not fully understood.
  • Further research is needed to clarify the effects of PCSK9 inhibition on glycemic parameters in patients with DM.
  • Understanding PCSK9's regulation in diabetes may reveal novel therapeutic targets.